drugset / Trial / NCT07046923
A Study of LY4175408 in Participants With Advanced Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years.
Timeline
- Start
- 2025-07-28
- Primary completion
- 2030-07
- Completion
- 2030-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Cisplatin | Other / unclassified | — | Intravenous |
| Subject | LY4175408 | Other / unclassified | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |